comparative effectiveness

Research in Review

Hypofractionation Leads to Greater Toxicity in Patients with Prostate Cancer

03/29/2016

JCP Editors

A new study has failed to demonstrate hypofractionated radiotherapy as a non-inferior option to fractionated radiotherapy for patients with intermediate- or high-risk prostate cancer. In patients with genitourinary...

A new...

03/29/2016

Journal of Clinical Pathways

Patients With Prostate Cancer Report Better QoL With Active Surveillance

03/16/2016

JCP Editors

Active surveillance (AS) for patients with low-risk prostate cancer can provide similar quality of life to that of men living without cancer, according to a study presented at the European Association of Urology...

Active...

03/16/2016

Journal of Clinical Pathways

Research in Review

Imatinib Projected to Be Most Cost-Effective Option for CML

03/14/2016

JCP Editors

According to researchers, imatinib is projected to become the most cost-effective initial treatment strategy for patients with chronic myeloid leukemia in chronic phase (CML-CP) after its patent expires later this...

...

03/14/2016

Journal of Clinical Pathways

Research in Review

Palliative Drugs In Combination With Docetaxel Can Improve Prostate Cancer Care

02/23/2016

JCP Editors

A clinical trial has shown that combining the chemotherapy drug docetaxel with other treatments can improve clinical outcomes in patients with bony metastatic castrate-refractory prostate cancer (CRPC). The...

A...

02/23/2016

Journal of Clinical Pathways

Research in Review

Ustekinumab Superior to Tumor Necrosis Factor-Alpha Inhibitors for the Treatment of Psoriasis

02/12/2016

JCP Editors

A study of the biologic drug ustekinumab has found it to be a better treatment for psoriasis than tumor necrosis factor-alpha (TNF-α) inhibitors. The PSOLAR (Psoriasis Longitudinal Assessment and Registry) study is...

A...

02/12/2016

Journal of Clinical Pathways

Research in Review

Predictive Biomarker for Panitumumab Therapy Effectiveness in Patients With Colorectal Cancer

02/12/2016

JCP Editors

Expression of epidermal growth factor receptor ligands epiregulin (EREG) and amphiregulin (AREG) may help determine which patients with colorectal cancer are the most likely to benefit from panitumumab therapy. The...

...

02/12/2016

Journal of Clinical Pathways

Research in Review

Proton Radiotherapy Equally Effective With Fewer Adverse Side Effects for Medulloblastoma

02/05/2016

JCP Editors

Proton radiotherapy is equally effective and causes fewer long-term side effects compared with standard photon (x-ray) radiation therapy (RT) for the treatment of pediatric patients with the most common type of...

Proton...

02/05/2016

Journal of Clinical Pathways

Research in Review

Common Outcome Measures for Clinical Trials Are Improving, Study Shows

01/28/2016

JCP Editors

According to a new study, core outcome sets (COS) for clinical trials have become more structured, but there remains a need for greater transparency and public engagement in how COS are developed. Clinical trials...

...

01/28/2016

Journal of Clinical Pathways

Research in Review

Radical Radiotherapy More Cost-Effective than Surgery Plus Radiotherapy for Cervical Cancer

01/28/2016

JCP Editors

Radical radiotherapy is more cost-effective for the treatment of cervical cancer than radical hysterectomy plus adjuvant radiotherapy, according to a recent study. National Comprehensive Cancer Network guidelines...

...

01/28/2016

Journal of Clinical Pathways

Research in Review

Nodal Upstaging More Common After Open Chest Surgery Than After VATS for Early-Stage Lung Cancer

01/22/2016

JCP Editors

Nodal upstaging after surgical intervention was found to be more common following open chest surgery approach to lobectomy for early-stage lung cancer compared with the closed-chest procedure known as video-assisted...

Nodal...

01/22/2016

Journal of Clinical Pathways